Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Thoracic 3Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Breast 2Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1

Conditions

Multiple Myeloma 5Recurrence 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × WW Domain-Containing Oxidoreductase × Plasma cell × Clear all
NCT02412878 2022-09-23

ARROW

Amgen

Phase 3 Completed
478 enrolled 17 charts
Plasma cell

Multiple Myeloma

NCT02335983 2020-11-06

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Amgen

Phase 1 Completed
107 enrolled 25 charts
Plasma cell

Multiple Myeloma

NCT00511238 2017-08-31

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Amgen

Phase 2 Completed
312 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT01980589 2017-05-30

CHAMPION 2

Amgen

Phase 1 Completed
22 enrolled 11 charts
Plasma cell

Multiple Myeloma

NCT00530816 2017-05-02

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Amgen

Phase 2 Completed
164 enrolled 16 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡